Skip to main content

Table 2 Characteristics before the risk of VAP, during ICU stay and main outcomes

From: Mortality, incidence, and microbiological documentation of ventilated acquired pneumonia (VAP) in critically ill patients with COVID-19 or influenza

Characteristics (median [IQR] or N(%))

Influenza (n = 82)

COVID-19 (n = 503)

p-value

Timing from ICU admission to intubation

1 [1; 2]

2 [1; 3]

 < 0.01

Treatments during ICU stay

 Selective digestive decontaminationa

0 (0)

54 (10.7%)

 < 0.01

 Prone position

18 (22)

262 (52.1)

 < 0.01

 RRT

24 (29.3)

161 (32)

0.62

 ECMO

5 (6.1)

54 (10.7)

0.20

 Vasopressors

19 (23.2)

341 (67.8)

 < 0.01

Nosocomial infections during ICU stay

 Bacteremia

16 (19.5)

108 (21.5)

0.69

 Fungemia

2 (2.4)

48 (9.5)

0.03

 VAP

23 (28)

209 (41.6)

0.02

 Early VAP (during the first 7 days)

6 (7.3)

85 (16.9)

0.03

 Late VAP (after day 7)

19 (23.2)

161 (32)

0.11

Main outcome measures

 Duration of invasive mechanical ventilation

12 [6; 22]

13 [7; 23]

0.41

 Duration of RRT

9 [4.5; 16.5]

10 [3; 18]

0.90

 Duration of ECMO

3 [1; 4]

12.5 [6; 19]

0.05

 Ventilatory-free days at day 28

11 [0; 21]

0 [0; 15]

 < 0.01

 RRT-free days at day 28

28 [15; 28]

25 [0; 28]

 < 0.01

 ECMO-free days at day 28

28 [28; 28]

28 [0; 28]

 < 0.01

 ICU LOS

14.5 [9; 28]

16 [10; 28]

0.37

 Hospital LOS

30.5 [13; 48]

22 [14; 40]

0.11

 Mortality at day 60

19 (23.2)

233 (46.3)

 < 0.01

  1.  VAP ventilator-associated pneumonia, ICU intensive care unit, RRT renal replacement therapy, ECMO extra corporeal membrane oxygenation, LOS length of stay
  2. aWithout intravenous antimicrobial therapy